Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCCA. Kaseb,D. G. Duda,H. S. Tran Cao,Y. I. Abugabal,L. M. Vence,A. Rashid,R. Carmagnani Pestana,J. M. Blando,S. Singh,J. N. Vauthey, Y. S. Chun,C-W. D. Tzeng, D. Sakamuri,R. A. Wolff,J. C. Yao,J. Allison,P. SharmaANNALS OF ONCOLOGY（2019）引用 47|浏览36暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
